The vaccine that has so far been approved for use in the U.S. is based on RNA, a relatively new vaccine technology. The vaccine delivers information on RNA molecules, which are inherently unstable. That’s partly why they need to be kept at extremely cold temperatures. Corey Casper, president and CEO of the Infectious Disease Research Institute in Seattle, explains the challenges in delivering these new vaccines to everyone who needs them.
Contact “Think Out Loud®”
If you’d like to comment on any of the topics in this show, or suggest a topic of your own, please get in touch with us on Facebook or Twitter, send an email to thinkoutloud@opb.org, or you can leave a voicemail for us at 503-293-1983. The call-in phone number during the noon hour is 888-665-5865.
THANKS TO OUR SPONSOR:
THANKS TO OUR SPONSOR: